A study has assessed the effect of Pentoxifylline [ Trental ] on proteinuria and renal function in chronic kidney disease ( CKD ) treatment.
Researchers systematically searched randomized and non-randomized controlled trials comparing Pentoxifylline to placebo, no treatment or renin-angiotensin system blockade in proteinuric CKD patients.
The outcomes concerning proteinuria, renal function, blood pressure and adverse events were extracted.
Twelve trials with 613 participants were identified.
Pentoxifylline significantly decreased proteinuria [ weighted mean difference ( WMD ) −0.60 g/day ( 95 % CI −0.84 to −0.36 ); p less than 0.001 ] compared to placebo or no-treatment groups, but the decrease was not significant [ WMD: 0.10 g/day ( −0.34 to 0.54 ); p = 0.66 ] compared to Captopril treatment.
The decrease of glomerular filtration rate was significantly less [ WMD: 3.67 ml/min ( 2.71–4.62 ); p less than 0.001 ] in the Pentoxifylline group than in the controls.
There was no significant difference in serum creatinine [ WMD: −0.03 mg/dl ( −0.10 to 0.03 ); p = 0.28 ], diastolic blood pressure [ WMD: 0.94 mmHg ( −0.74 to 2.61 ); p = 0.27 ] and adverse events [ RR: 0.89 ( 0.60 to 1.32 ); p = 0.56 ].
In conclusion, Pentoxifylline may decrease proteinuria and protect renal function in patients with chronic kidney disease. Further studies are needed to confirm this result. ( Xagena )
Jiang X et al, J Nephrol 2015; First online